Literature DB >> 28157601

Prognostic factors in patients with refractory idiopathic generalized epilepsy.

A Gomez-Ibañez1, R S McLachlan2, S M Mirsattari3, D C Diosy4, J G Burneo5.   

Abstract

OBJECTIVE: Idiopathic generalized epilepsy (IGE) is an epileptic condition with good response to antiepileptic drugs (AED). Major syndromes are epilepsy with generalized tonic-clonic seizures (GTCS) alone, absence epilepsy and juvenile myoclonic epilepsy. However, clinical practice shows drug-resistant patients. Endpoint is to identify clinical features related with refractoriness in IGE and in its each individual syndrome.
METHODS: We retrospectively collected 279 consecutive patients with IGE assessed in the Epilepsy Clinic of our institution. We defined drug-resistant epilepsy as a failure of adequate trials of 2 tolerated and appropriately chosen and used AED schedules. We classified patients in two groups: drug-resistant and drug-responsive. Clinical features were compared among these groups, in the whole IGE group as well as in each syndrome.
RESULTS: There were 122 drug-resistant, 105 drug- responsive; 52 were undefined and excluded from the analysis. After multivariate analysis, early seizures onset (age <13), long-time epilepsy, several generalized seizure types, status epilepticus, EEG with generalized epileptiform activity, mainly polyspikes, and side effects with AED brought up as poor outcome factors. Additionally, 50.6% identified modifiable seizure triggers. Regarding syndromes, epilepsy with generalized tonic-clonic seizures alone had the same factors except several seizure types; presence of additional GTCS, polyspikes, history of AED side effects and psychiatric disorder were poor factors for absence epilepsy; only psychiatric comorbidity revealed significance in juvenile myoclonic epilepsy. SIGNIFICANCE: Refractoriness in IGE and its major syndromes is associated with clinical and electrographic parameters. Moreover, lifestyle advices from neurologists to the patients might help them to achieve a better seizure control.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug-resistance; Generalized epilepsy; Lifestyle; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28157601     DOI: 10.1016/j.eplepsyres.2017.01.011

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

Review 1.  Intractable Generalized Epilepsy: Therapeutic Approaches.

Authors:  Sean T Hwang; Scott J Stevens; Aradia X Fu; Simona V Proteasa
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-26       Impact factor: 5.081

2.  Community-informed connectomics of the thalamocortical system in generalized epilepsy.

Authors:  Zhengge Wang; Sara Larivière; Qiang Xu; Reinder Vos de Wael; Seok-Jun Hong; Zhongyuan Wang; Yun Xu; Bin Zhu; Neda Bernasconi; Andrea Bernasconi; Bing Zhang; Zhiqiang Zhang; Boris C Bernhardt
Journal:  Neurology       Date:  2019-08-12       Impact factor: 9.910

Review 3.  Surgical Treatment of Drug-Resistant Generalized Epilepsy.

Authors:  Katie L Bullinger; Abdulrahman Alwaki; Robert E Gross
Journal:  Curr Neurol Neurosci Rep       Date:  2022-06-17       Impact factor: 6.030

Review 4.  Recent Advances in Neuroimaging of Epilepsy.

Authors:  Adam M Goodman; Jerzy P Szaflarski
Journal:  Neurotherapeutics       Date:  2021-05-03       Impact factor: 7.620

5.  The long-term prognosis of epilepsy patients with medically treated over a period of eight years in Turkey.

Authors:  Pelin Duman; Asuman Orhan Varoglu; Esra Kurum
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

6.  Current Concepts in the Management of Idiopathic Generalized Epilepsies.

Authors:  Chaturbhuj Rathore; Kajal Y Patel; Parthasarthy Satishchandra
Journal:  Ann Indian Acad Neurol       Date:  2022-02-01       Impact factor: 1.383

7.  Development and validation of a predictive model of drug-resistant genetic generalized epilepsy.

Authors:  Hyunmi Choi; Kamil Detyniecki; Carl Bazil; Suzanne Thornton; Peter Crosta; Hatem Tolba; Manahil Muneeb; Lawrence J Hirsch; Erin L Heinzen; Arjune Sen; Chantal Depondt; Piero Perucca; Gary A Heiman
Journal:  Neurology       Date:  2020-08-05       Impact factor: 9.910

Review 8.  Layer-By-Layer: The Case for 3D Bioprinting Neurons to Create Patient-Specific Epilepsy Models.

Authors:  Natasha Antill-O'Brien; Justin Bourke; Cathal D O'Connell
Journal:  Materials (Basel)       Date:  2019-10-01       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.